AU2015208666B2 - Treatment of neoplasia - Google Patents

Treatment of neoplasia Download PDF

Info

Publication number
AU2015208666B2
AU2015208666B2 AU2015208666A AU2015208666A AU2015208666B2 AU 2015208666 B2 AU2015208666 B2 AU 2015208666B2 AU 2015208666 A AU2015208666 A AU 2015208666A AU 2015208666 A AU2015208666 A AU 2015208666A AU 2015208666 B2 AU2015208666 B2 AU 2015208666B2
Authority
AU
Australia
Prior art keywords
dose
treatment
patient
infusion
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015208666A
Other languages
English (en)
Other versions
AU2015208666A1 (en
Inventor
David Cade
Michael TAPNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtex Medical Pty Ltd
Original Assignee
Sirtex Medical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900232A external-priority patent/AU2014900232A0/en
Application filed by Sirtex Medical Pty Ltd filed Critical Sirtex Medical Pty Ltd
Priority to AU2015208666A priority Critical patent/AU2015208666B2/en
Publication of AU2015208666A1 publication Critical patent/AU2015208666A1/en
Application granted granted Critical
Publication of AU2015208666B2 publication Critical patent/AU2015208666B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015208666A 2014-01-24 2015-01-23 Treatment of neoplasia Active AU2015208666B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015208666A AU2015208666B2 (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2014900232A AU2014900232A0 (en) 2014-01-24 Treatment of Neoplasia
AU2014900232 2014-01-24
AU2015208666A AU2015208666B2 (en) 2014-01-24 2015-01-23 Treatment of neoplasia
PCT/AU2015/000037 WO2015109367A1 (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Publications (2)

Publication Number Publication Date
AU2015208666A1 AU2015208666A1 (en) 2016-09-01
AU2015208666B2 true AU2015208666B2 (en) 2019-08-22

Family

ID=53680513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015208666A Active AU2015208666B2 (en) 2014-01-24 2015-01-23 Treatment of neoplasia

Country Status (12)

Country Link
US (1) US10849900B2 (enExample)
EP (1) EP3096752A4 (enExample)
JP (1) JP2017503846A (enExample)
KR (1) KR102317751B1 (enExample)
CN (1) CN106102735A (enExample)
AU (1) AU2015208666B2 (enExample)
BR (1) BR112016016932A8 (enExample)
CA (1) CA2937015C (enExample)
IL (1) IL246880B (enExample)
PH (1) PH12016501407A1 (enExample)
SG (1) SG11201605900VA (enExample)
WO (1) WO2015109367A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107246A1 (en) * 2016-12-16 2018-06-21 The Australian National University Improving selective internal radiation therapy
US10992078B2 (en) 2018-01-29 2021-04-27 Bard Access Systems, Inc. Connection system for establishing an electrical connection through a drape and methods thereof
US10772696B2 (en) 2018-05-18 2020-09-15 Bard Access Systems, Inc. Connection systems and methods thereof for establishing an electrical connection through a drape
CA3132792A1 (en) 2019-05-15 2020-11-19 Boston Scientific Scimed, Inc. Medical device having asymmetric bending
CN112206400B (zh) 2019-07-12 2025-02-28 巴德阿克塞斯系统股份有限公司 包括发光二极管阵列的导管跟踪和放置系统
CA3150924A1 (en) 2019-08-08 2021-02-11 Bard Access Systems, Inc. Optical-fiber connector modules including shape-sensing systems and methods thereof
JP2024522704A (ja) * 2021-06-14 2024-06-21 ノボキュア ゲーエムベーハー 交流電場、放射性粒子、及び全身療法を用いたがんの治療及び予防の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002629A1 (en) * 2003-07-02 2005-01-13 Sirtex Medical Limited Combination therapy of oxaliplatin and radioactively doped particles treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6379648B1 (en) 1999-02-01 2002-04-30 The Curators Of The University Of Missouri Biodegradable glass compositions and methods for radiation therapy
WO2000045826A1 (en) 1999-02-02 2000-08-10 The Curators Of The University Of Missouri Process for making ceramic microspheres
AUPR098200A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Production of low density radionuclide containing microspheres
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002629A1 (en) * 2003-07-02 2005-01-13 Sirtex Medical Limited Combination therapy of oxaliplatin and radioactively doped particles treating cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Anonymous., "FOLFOX plus SIR-spheres microspheres versus FOLFOX alone in patients with liver mets from primary colorectal cancer (SIRFLOX)", 2013-11-07, ClinicalTrials.gov - U.S. NIH https://clinicaltrials.gov/ct2/show/NCT00724503 *
GULEC, S.A., "Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double- arm-controlled phase II trial." AM J CLIN ONCOL. 2013-10 v.36, n.5, p455-460 *
HREHORET, D. ET AL., "Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report.", CHIRURGIA., (2013-09), vol. 108, no. 5, pages 719 - 724 *
KOSMIDER, S. ET AL., "Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.", J VASC INTERV RADIOL., (2011-06), vol. 22, no. 6, pages 780 - 786 *
SHARMA, R.A. et al. "Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy" J CLIN ONCOL. 2007-03-20 v.25, n.9, p1099-1106 *
SHARMA, R.A. ET AL., "FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer.", CLIN ONCOL., (2008-04), vol. 20, no. 3, pages 261 - 263 *
VENTE, M. A. ET AL., "Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.", EUROPEAN RADIOLOGY., (2009-04), vol. 19, no. 4, pages 951 - 959 *

Also Published As

Publication number Publication date
US10849900B2 (en) 2020-12-01
BR112016016932A8 (pt) 2020-06-16
NZ723150A (en) 2021-05-28
PH12016501407A1 (en) 2016-08-31
SG11201605900VA (en) 2016-08-30
KR102317751B1 (ko) 2021-10-27
EP3096752A4 (en) 2017-10-18
IL246880A0 (en) 2016-08-31
US20170000795A1 (en) 2017-01-05
JP2017503846A (ja) 2017-02-02
CN106102735A (zh) 2016-11-09
KR20160122142A (ko) 2016-10-21
CA2937015A1 (en) 2015-07-30
CA2937015C (en) 2022-08-02
EP3096752A1 (en) 2016-11-30
AU2015208666A1 (en) 2016-09-01
BR112016016932A2 (pt) 2017-08-08
IL246880B (en) 2021-10-31
WO2015109367A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2015208666B2 (en) Treatment of neoplasia
Lewandowski et al. Transcatheter intraarterial therapies: rationale and overview
Benson III et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study
AU2015255622B2 (en) Method for treating renal cell carcinoma
US20060115424A1 (en) Combination therapy of oxaliplatin and radioactively doped particles treating cancer
CA2926771A1 (en) Cancer treatment with combination of plinabulin and taxane
EP2895206A1 (en) Method of treating cancer
US20040220135A1 (en) Combination therapy for treatment of neoplasia
US10232063B2 (en) Method for treating lung carcinoma
Murphy et al. Topoisomerase I inhibitors in the treatment of head and neck cancer
Cho et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma
Kempf et al. Limb salvage surgery for bone and soft tissue sarcoma. A phase II pathologic study of preoperative intraarterial cisplatin
NZ723150B2 (en) Treatment of neoplasia
AU2014203772B2 (en) Method for Treating Lung Carcinoma
US20250249133A1 (en) Radioembolic beads and methods for treatment of tumor cells
Lee et al. Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer
Wasan The Role of Radioembolisation Using SIR-Spheres® in Secondary Liver Metastases of Non-colorectal Cancer Origin–Emerging Clinical Data
AU2003203953A1 (en) Combination Therapy for Treatment of Neoplasia
HK1230494B (en) Microparticles for treating renal cell carcinoma
HK1230494A1 (en) Microparticles for treating renal cell carcinoma
Ibrahim et al. Internal radioembolization for colorectal carcinoma liver metastases
CA2856389A1 (en) Method for treating lung carcinoma
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GM Mortgages registered

Name of requester: BANK OF CHINA LIMITED MACAU BRANCH

GM Mortgages registered

Name of requester: CHINA CITIC BANK INTERNATIONAL LIMITED

GMD Discharge of a mortgage

Effective date: 20211027

GMD Discharge of a mortgage

Effective date: 20240708